- Home
- AGMH vs CDT Comparison
AGMH vs CDT Comparison
Compare AGMH & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- CDT
- Stock Information
- Founded
- AGMH 2015
- CDT 2019
- Country
- AGMH Hong Kong
- CDT United States
- Employees
- AGMH N/A
- CDT N/A
- Industry
- AGMH EDP Services
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- CDT Health Care
- Exchange
- AGMH Nasdaq
- CDT Nasdaq
- Market Cap
- AGMH 3.9M
- CDT 4.6M
- IPO Year
- AGMH 2018
- CDT N/A
- Fundamental
- Price
- AGMH $2.33
- CDT $0.60
- Analyst Decision
- AGMH
- CDT
- Analyst Count
- AGMH 0
- CDT 0
- Target Price
- AGMH N/A
- CDT N/A
- AVG Volume (30 Days)
- AGMH 734.4K
- CDT 2.3M
- Earning Date
- AGMH 05-13-2025
- CDT 08-14-2025
- Dividend Yield
- AGMH N/A
- CDT N/A
- EPS Growth
- AGMH N/A
- CDT N/A
- EPS
- AGMH 6.43
- CDT N/A
- Revenue
- AGMH $32,044,575.00
- CDT N/A
- Revenue This Year
- AGMH N/A
- CDT N/A
- Revenue Next Year
- AGMH N/A
- CDT N/A
- P/E Ratio
- AGMH $0.33
- CDT N/A
- Revenue Growth
- AGMH N/A
- CDT N/A
- 52 Week Low
- AGMH $1.09
- CDT $0.57
- 52 Week High
- AGMH $109.50
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- AGMH 55.05
- CDT 14.33
- Support Level
- AGMH $1.92
- CDT $0.57
- Resistance Level
- AGMH $4.38
- CDT $1.36
- Average True Range (ATR)
- AGMH 0.47
- CDT 0.09
- MACD
- AGMH 0.05
- CDT -0.06
- Stochastic Oscillator
- AGMH 29.19
- CDT 2.50
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.